ūüďě  +1 (855) 661-4441(US)   ūüďě  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Uveitis Treatment Market Research Report Information By Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Others), Drug Class (Corticosteroids Drugs, Anti-Inflammatory Drugs, Immunosuppressive Drugs) and End-User (Hospitals, Specialty Clinics)- Forecast to 2032

ID: MRFR/HC/6985-HCR | 125 Pages | Author: Rahul Gotadki| June 2024

Global Uveitis Treatment Market Overview

The Uveitis Treatment Market Size was valued at USD 0.66 Billion in 2023. The Global Uveitis Treatment industry is projected to grow from USD 0.70 Billion in 2024 to USD 1.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.98% during the forecast period (2024 - 2032). Uveitis is a form of inflammation that occurs in the middle layer of the eyeball known as the uvea. It is accompanied by symptoms such as pain, redness of the eyes, and blurred vision. It mainly occurs in people aged between 20 to 50 years. There are three main types of uveitis anterior uveitis, posterior uveitis, and intermediate uveitis.

For instance, in June 2016, AbbVie Inc received FDA (Food and Drug Administration) approvals for its HUMIRA in the treatment of non-infectious intermediate, posterior, and panuveitis. This helped it to strengthen its uveitis treatment product portfolio.

A key factor propelling the uveitis treatment market is the worldwide increase in uveitis incidence and prevalence. The increased incidence of uveitis can be attributed to a number of factors, including autoimmune illnesses, infections, and inflammatory disorders. Moreover, the therapy of uveitis has also been progressed thanks to the discovery of new drugs such biologic treatments, immunosuppressants, and targeted medicines. 

The development of more precise and efficient methods of treatment is a major factor driving the market forward. Therefore, the early diagnosis and quick treatment of uveitis have resulted from rising awareness about the condition among healthcare professionals and patients. As a result, there is a greater need for effective treatments for uveitis.

Rapid market expansion may be attributed, in part, to the increase in spending on research projects in the ophthalmology sector. Refractory posterior or intermediate uveitis are the subject of a growing number of clinical trials across the world. Several randomized, controlled trials of alternative treatments to the conventional corticosteroid therapy for noninfectious uveitis, such as mycophenolate mofetil and methotrexate, are currently enrolling patients.

Moreover, the improvement of therapy choices for ocular inflammatory problems is largely attributable to the creation of biological therapies through intensive R&D efforts. As a result, this is increasing the need for these medications and stimulating the market.

May 2023:The Israeli firm BioNanoSim will partner with the Greek manufacturer RAFARM to launch BNS Ophthalmics (BNSO), which will sell pharmaceuticals designed by BNS to treat critical eye illnesses. The company's flagship product, BNSO-1, is a topically applied anti-inflammatory drug. Chronic Anterior Uveitis is an inflammation of the iris that can be caused by a number of infectious and noninfectious disorders. By the end of the year, BNSO plans to begin a clinical research employing the innovative medication in patients with this condition. 

Uveitis Treatment Market Trends

Rising prevalence of uveitis, increasing R&D expenditure, and product launches are likely to impact the growth of the uveitis treatment market positively.

Market Drivers

Increased R&D expenditure in the healthcare industry will support the growth of the uveitis treatment market.
The growth of the market is driven by the increasing number of product launches in the uveitis treatment market. For example, in October 2018, EyePoint Pharmaceuticals received FDA approval for Yutiq (fluocinolone acetonide intravitreal implant). This product is used in the treatment of chronic non-infectious uveitis.
Increasing prevalence of the uveitis across the globe

Market Restraints

Side-effect related to corticosteroid drugs is likely to hamper the growth of the uveitis treatment market during the forecast period

Uveitis Treatment Market Segment Insights

Uveitis Treatment Type Insights

Anterior Uveitis: In anterior uveitis, inflammation forms in the middle layer of the eye that includes the iris and adjacent tissue. This segment holds the most significant share in the type segment. Mainly topical drops such as corticosteroid drops are prescribed by the physician in the treatment of the anterior uveitis.
Intermediate Uveitis: It occurs in children as well as young adults. It accounts for 2% 31% of all uveitis patients and incidence of the intermediate uveitis between 1.4% to 2% in Germany.
Posterior Uveitis: In posterior uveitis, the inflammation primarily forms in the retina and choroid area of the eye.

Uveitis Treatment Drug Class Insights

Corticosteroids Drugs: This drug class is most commonly used for the treatment of uveitis. It expected to hold the largest share in the uveitis treatment market due to the increasing preference of this drug class and desirable outcomes. Major corticosteroid brands in the uveitis treatment market are Ozurdex (Allergan PLC) and Triesence suspension (Novartis AG).
Anti-Inflammatory Drugs: In chronic uveitis, non-steroid anti-inflammatory drugs are used to treat inflammation over a more extended period.
Immunosuppressive Drugs: Maximum immunosuppressive agents have significant adverse effects due to which these drugs are not used very often for the treatment of the uveitis.

Uveitis Treatment End-User Insights

Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals. In 2018, the hospital's segment held the largest share of the uveitis treatment market.
Specialty Clinics: Consisting of long-term care for chronic patients and the elderly, this is a fast-growing market segment, especially in developed nations.

January 2023:Active Biotech reported that their phase I clinical research of an eye drop formulation of laquinimod in healthy participants had been successfully completed. Inflammatory eye illnesses, such as non-infectious uveitis, a sight-threatening eye condition, have an unmet medical need for more therapeutic therapies with a favorable safety and tolerability profile. No safety problems or local toxicity issues were found with the dose regimens examined for the laquinimod eye drop in this trial, which is a promising sign. 

August 2023:A local ocular delivery patent for the KIO-100 family of non-steroidal anti-inflammatory small compounds was issued in the United States (Patent No. 11,730,716) and Europe in August 2023, as reported by Kiora Pharmaceuticals, Inc. In addition to protecting Kiora's pipeline, this IP also extends market exclusivity for approved indications in the United States and Europe for a number of inflammatory-related therapeutic applications, such as the treatment of posterior non-infectious uveitis.

Uveitis Treatment Regional Insights

Americas:The Americas held the largest regional uveitis treatment market in 2018. The US has over 7,200 active hospitals and a well-established healthcare sector. This serves to drive development in the region's market for uveitis treatment.
Additionally, increasing the incidence of uveitis in the US is likely to support the growth of the uveitis treatment market. The annual rate of uveitis around 26.6 to 102 per 100,000 adults in the US. Moreover, uveitis has led to about 2.8% of cases of blindness in the US.
Europe: The need for uveitis treatment is high in this region due to the rising prevalence of the uveitis in the region.
Asia-Pacific: The Asia-Pacific is the fastest-growing region for the uveitis treatment market. It has the world’s largest population and a fast-developing healthcare sector.
Middle East & Africa: It is projected to account for the least share of the uveitis treatment market due to low per capita disposable incomes in the region and limited development of healthcare facilities.

Uveitis Treatment Market Key Players

  • Allergan PLC (Ireland)

  • Bausch Health (Canada) 

  • Novartis AG (Switzerland)

  • EyePoint Pharmaceuticals, Inc. (US)

  • AbbVie Inc. (US)

  • Horizon Therapeutics Plc (Ireland)

  • Mylan NV (US)

  • Alimera Sciences (US)

  • Others

Report Attribute/Metric Details
  Market Size   2032: 1.14 Billion
  CAGR   2024-2032: 6.98%
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Drug Class, End-User, Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergan PLC (Ireland), Novartis AG (Switzerland), Bausch Health (Canada), EyePoint Pharmaceuticals, Inc. (US), AbbVie Inc. (US), Horizon Therapeutics Plc (Ireland), Mylan NV (US), Alimera Sciences (US)
  Key Market Opportunities Product Launch Merger & Acquisition
  Key Market Drivers Increased R&D expenditure Increasing number of product launches

Frequently Asked Questions (FAQ) :

The most common Symptoms of uveitis such as pain, redness of the eyes, and blurred vision.

The uveitis treatment market is projected to grow at approximately 6.98% CAGR during the forecast period.

Increasing numbers of product launches.

North America holds the largest share in the global uveitis treatment market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), Allergan PLC (Ireland), Bausch Health (Canada), AbbVie Inc. (US), EyePoint Pharmaceuticals, Inc. (US), Horizon Therapeutics Plc (Ireland), Alimera Sciences (US), and Mylan NV (US), are some of the major players operating in the uveitis treatment market.

The valuation of the uveitis treatment market is estimated to reach USD 1.14 Billion during the forecast period.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.